Clinical Research Directory

Inclusion criteria: 1. Total body weight of ≥40 kg. 2. Must have pathologically confirmed relapsed or refractory acute myeloid leukemia (R/R AML) including: 1. Relapsed AML is defined as ≥5% blasts in the bone marrow (BM) or peripheral blood at any time after achieving a CR, CRh, Cri, or MLFS. 2. Refractory AML is defined as failure to achieve a CR, CRh, Cri, or MLFS after 1 of the following regimens: i. Two courses of intensive induction chemotherapy. ii. At least 2 cycles of hypomethylating agent (HMA) or low-dose, cytarabine-based combination regimen. iii. At least 4 cycles of HMA monotherapy. 3. During dose escalation, participants must be ineligible for hematopoietic stem cell transplantation (HSCT). 4. Must have an anticipated life expectancy of \>3 months before lymphodepletion. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 6. Participants must have adequate renal, cardiac, hepatic, pulmonary and bone marrow function as defined by the protocol. Exclusion criteria: 1. Diagnosis of acute promyelocytic leukemia. 2. Has received or plans to receive any of the excluded therapy/treatment within the specified timeframe before lymphodepleting chemotherapy as defined by the protocol. 3. Prior allogeneic HSCT within 3 months of signing informed consent form (ICF) or with ongoing requirement for systemic graft-versus-host therapy. 4. Active central nervous system (CNS) involvement. 5. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (eg. cervix, bladder, breast) low grade prostate cancer without treatment requirement unless in remission without treatment for ≥2 years.